Last updated 2026-06-18
- Raised funding round, Sep 2018
Total raised
—
Last: 2018-09
Stage
Seed
Founded
2018
Headcount
4
HQ
, Israel
Sector
Health Tech & Life Sciences
About
Ramino Bio is developing an oral drug to treat cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD). Ramino Bio’s unique technology addresses the unmet need of several metabolic diseases in the emerging novel elevated BCAA (Branched-chain amino acid) field. With a druggable lead compound, showing efficacy in-vivo, Ramino Bio is heading preclinical stages. First-in-human studies are planned within 18 months with our lead candidate. We are committed to developing effective therapies for the benefit of the patients.
Funding history · 1 round · — total
Q&A
- What is Ramino-Bio's primary focus?
- Ramino-Bio is developing an oral drug to treat cardio-metabolic diseases and rare Maple Syrup Urine Disease (MSUD).
- When was Ramino-Bio founded?
- Ramino-Bio was founded in September 2018.
- What is the current status of Ramino-Bio?
- Ramino-Bio is currently inactive, having ceased to operate in November 2025.
- How many employees does Ramino-Bio have?
- Ramino-Bio has 1-10 employees.
- Which investors participated in Ramino-Bio's funding round in September 2018?
- Investors in Ramino-Bio's September 2018 funding round included Johnson & Johnson Innovation.
- What is Ramino-Bio's current funding stage?
- Ramino-Bio is currently in the Seed funding stage.
- Where is Ramino-Bio's headquarters located?
- Ramino-Bio's headquarters is located in Ness Ziyyona, Israel.
- What is the product stage of Ramino-Bio's development?
- Ramino-Bio's product is in the R&D stage.
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 PatentsVerified
Tags
rare-diseasesbiopharmaceuticaltreatmentspharmaceuticalsmetabolic-diseasedrug-developmentcardiovascularbiotechnology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/93388496 |
Identifiers & details
| Founded | 2018-9 |
|---|---|
| Employees (exact) | 4 |
| Status reason | Non Active, Nov 2025 ceased to operate |